Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pancreatic cancer.

Donghui Li1, Keping Xie, Robert Wolff

  • 1Department of Gastrointestinal Medical Oncology, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 426, Houston, TX 77030, USA.

Lancet (London, England)
|March 31, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasmonic Re-Excitation Enables Superoxide-Mediated Ethane Conversion to Acetic Acid under Visible Light.

Journal of the American Chemical Society·2026
Same author

Integrative machine learning and experimental validation reveal the molecular mechanisms of 2-bromo-4,6-dinitroaniline nephrotoxicity: CD45 and cyclophilin C as early response biomarkers of renal tubular injury.

Toxicology and applied pharmacology·2026
Same author

Interacting and joint effects of frailty and depressive symptoms in relation to risk of cardio-oncology comorbidity in older adults from three prospective cohorts.

BMC geriatrics·2026
Same author

Addressing phase instability and charge recombination in pyrolysis-synthesized BiVO<sub>4</sub> via DFT-guided Mo doping for enhanced performance.

National science review·2026
Same author

Denitrification vs. assimilation: shifting metabolic pathways to enable N recovery from low-strength municipal wastewater.

Bioresource technology·2026
Same author

Unlocking the Solution Processability of Graphene Nanoribbons via a Solvent-Assisted Direct Fluorination.

ACS applied materials & interfaces·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
See all related articles

Pancreatic cancer has a poor prognosis, with limited treatment options and high mortality. Advances in understanding its molecular biology offer hope for developing more effective therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Pancreatic cancer is a significant health challenge with poor outcomes.
  • Conventional treatments are largely ineffective, and most patients develop fatal metastases.
  • Key risk factors include smoking, age, and genetic predispositions, but primary causes remain unclear.

Purpose of the Study:

  • To review the current understanding of pancreatic cancer pathogenesis.
  • To discuss the limitations of existing treatments.
  • To highlight promising new therapeutic strategies.

Main Methods:

  • Review of molecular biology advances in understanding pancreatic cancer.
  • Analysis of current treatment modalities and their palliative benefits.

Related Experiment Videos

  • Exploration of emerging therapeutic approaches.

    • Main Results:

    • Pancreatic cancer pathogenesis involves K-ras oncogene mutations and inactivated tumor-suppressor genes.
    • Growth factors play a critical role in disease progression.
    • Current treatments offer limited survival benefits, with 5-year survival around 20% for resectable cases.

    Conclusions:

    • Pancreatic cancer remains resistant to current therapies, necessitating novel approaches.
    • Investigational methods like preoperative chemoradiation and expanded use of gemcitabine are being explored.
    • Therapeutic strategies targeting the molecular underpinnings of pancreatic cancer hold the greatest promise for improved patient outcomes.